| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.
|
Autophagy
|
2007
|
20.92
|
|
2
|
How I treat extramedullary acute myeloid leukemia.
|
Blood
|
2011
|
3.42
|
|
3
|
Clinical practice. Superior vena cava syndrome with malignant causes.
|
N Engl J Med
|
2007
|
3.39
|
|
4
|
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.
|
J Clin Oncol
|
2006
|
2.99
|
|
5
|
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
|
J Clin Oncol
|
2007
|
2.62
|
|
6
|
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2010
|
2.45
|
|
7
|
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
|
Blood
|
2004
|
2.12
|
|
8
|
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.
|
Cancer
|
2006
|
2.09
|
|
9
|
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.
|
Cancer Res
|
2005
|
1.86
|
|
10
|
Radiation therapy for chloroma (granulocytic sarcoma).
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.76
|
|
11
|
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
|
Blood
|
2003
|
1.76
|
|
12
|
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
|
J Clin Oncol
|
2006
|
1.74
|
|
13
|
Second malignant neoplasms and cardiovascular disease following radiotherapy.
|
J Natl Cancer Inst
|
2012
|
1.64
|
|
14
|
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.
|
Blood
|
2004
|
1.55
|
|
15
|
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
Blood
|
2010
|
1.54
|
|
16
|
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
|
J Clin Oncol
|
2013
|
1.54
|
|
17
|
Multiple myeloma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2007
|
1.53
|
|
18
|
The role of radiation therapy in the management of primary central nervous system lymphoma.
|
Leuk Lymphoma
|
2014
|
1.48
|
|
19
|
NCCN clinical practice guidelines in oncology: multiple myeloma.
|
J Natl Compr Canc Netw
|
2009
|
1.44
|
|
20
|
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
|
Neurology
|
2007
|
1.43
|
|
21
|
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.42
|
|
22
|
Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice on outcome.
|
Leuk Lymphoma
|
2012
|
1.41
|
|
23
|
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.40
|
|
24
|
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.
|
J Clin Oncol
|
2003
|
1.39
|
|
25
|
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.
|
J Neurooncol
|
2008
|
1.36
|
|
26
|
Delayed neurotoxicity in primary central nervous system lymphoma.
|
Arch Neurol
|
2005
|
1.35
|
|
27
|
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
|
Blood
|
2011
|
1.31
|
|
28
|
Multiple myeloma.
|
J Natl Compr Canc Netw
|
2011
|
1.28
|
|
29
|
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
|
J Natl Compr Canc Netw
|
2007
|
1.26
|
|
30
|
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
|
J Clin Oncol
|
2008
|
1.26
|
|
31
|
Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.
|
Clin Lymphoma Myeloma
|
2006
|
1.25
|
|
32
|
Non-Hodgkin's lymphomas, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.20
|
|
33
|
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
|
Br J Haematol
|
2009
|
1.20
|
|
34
|
Non-Hodgkin's lymphomas, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.17
|
|
35
|
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
|
Br J Haematol
|
2006
|
1.17
|
|
36
|
Multiple myeloma, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.14
|
|
37
|
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
|
Br J Haematol
|
2010
|
1.11
|
|
38
|
Recurrent neurotropic chloroma: report of a case and review of the literature.
|
Adv Hematol
|
2010
|
1.09
|
|
39
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
40
|
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
|
Br J Haematol
|
2004
|
1.03
|
|
41
|
Non-Hodgkin's Lymphomas, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.03
|
|
42
|
Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients.
|
AJR Am J Roentgenol
|
2008
|
1.03
|
|
43
|
The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.02
|
|
44
|
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.
|
Br J Haematol
|
2004
|
1.00
|
|
45
|
Intensity-modulated radiotherapy for lymphoma involving the mediastinum.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.99
|
|
46
|
Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.97
|
|
47
|
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
|
Leuk Lymphoma
|
2005
|
0.95
|
|
48
|
Non-Hodgkin's lymphomas, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.94
|
|
49
|
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.
|
J Clin Oncol
|
2011
|
0.93
|
|
50
|
Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.93
|
|
51
|
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
|
Br J Haematol
|
2005
|
0.92
|
|
52
|
Radiation treatment planning techniques for lymphoma of the stomach.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.91
|
|
53
|
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.
|
Clin Cancer Res
|
2002
|
0.90
|
|
54
|
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
|
J Natl Compr Canc Netw
|
2012
|
0.89
|
|
55
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
J Natl Compr Canc Netw
|
2016
|
0.89
|
|
56
|
Hodgkin lymphoma.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
57
|
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
|
Cancer
|
2008
|
0.87
|
|
58
|
Cutaneous Rosai-Dorfman disease of the right ear responsive to radiotherapy.
|
J Am Acad Dermatol
|
2012
|
0.85
|
|
59
|
Advances in biology, diagnostics, and treatment of Hodgkin's disease.
|
Biol Blood Marrow Transplant
|
2006
|
0.85
|
|
60
|
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.84
|
|
61
|
Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literature.
|
Cancer J
|
2004
|
0.84
|
|
62
|
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
|
PLoS One
|
2016
|
0.84
|
|
63
|
Second malignant neoplasms and cardiovascular disease following radiotherapy.
|
Health Phys
|
2014
|
0.83
|
|
64
|
Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.
|
PLoS One
|
2013
|
0.82
|
|
65
|
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.82
|
|
66
|
Hodgkin lymphoma, version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.82
|
|
67
|
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
|
Neurology
|
2005
|
0.81
|
|
68
|
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
69
|
Multiple Myeloma, Version 2.2016.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
70
|
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
|
J Clin Oncol
|
2008
|
0.81
|
|
71
|
Successful management of gastric perforation in stage IV diffuse large B-cell lymphoma with chemoradiation therapy, percutaneous endoscopy gastrostomy for gastric drainage, and percutaneous endoscopy jejunostomy for nutrition.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.80
|
|
72
|
Imaging of late complications from mantle field radiation in lymphoma patients.
|
Radiol Clin North Am
|
2008
|
0.80
|
|
73
|
Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy.
|
Eur J Haematol Suppl
|
2005
|
0.80
|
|
74
|
Pathways that regulate autophagy and their role in mediating tumor response to treatment.
|
Autophagy
|
2006
|
0.80
|
|
75
|
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.79
|
|
76
|
[¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.79
|
|
77
|
Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy.
|
Leuk Lymphoma
|
2012
|
0.79
|
|
78
|
Evidence-based breast cancer screening guidelines for women who received chest irradiation at a young age.
|
J Clin Oncol
|
2013
|
0.79
|
|
79
|
Retinopathy in survivors of primary central nervous system lymphoma.
|
Neurology
|
2006
|
0.78
|
|
80
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2008
|
0.78
|
|
81
|
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.78
|
|
82
|
Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
|
J Clin Oncol
|
2010
|
0.78
|
|
83
|
Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
84
|
Clinical features and outcome of primary pancreatic lymphoma.
|
Ann Surg Oncol
|
2014
|
0.77
|
|
85
|
Whole-brain radiotherapy in primary CNS lymphoma.
|
Lancet Oncol
|
2011
|
0.77
|
|
86
|
Sarcoid in cancer patients: clinical characteristics and associated disease status.
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2015
|
0.77
|
|
87
|
Breast cancer after Hodgkin disease: hope for a safer cure.
|
JAMA
|
2003
|
0.77
|
|
88
|
Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma.
|
J Clin Oncol
|
2006
|
0.77
|
|
89
|
The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.
|
Expert Rev Anticancer Ther
|
2011
|
0.76
|
|
90
|
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
|
J Clin Oncol
|
2010
|
0.75
|
|
91
|
Contrast media use in radiation oncology: a prospective, controlled educational intervention study with retrospective analysis of patient outcomes.
|
J Am Coll Radiol
|
2010
|
0.75
|
|
92
|
Cancer Survivorship. Preface.
|
Hematol Oncol Clin North Am
|
2008
|
0.75
|
|
93
|
Cancer survivorship: facing forward.
|
Hematol Oncol Clin North Am
|
2008
|
0.75
|
|
94
|
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
95
|
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy.
|
J Clin Oncol
|
2005
|
0.75
|
|
96
|
Hodgkin disease/lymphoma.
|
J Natl Compr Canc Netw
|
2008
|
0.75
|